共 49 条
- [31] Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) CellsBLOOD, 2017, 130Heine, SimonSilkenstedt, ElisabethDengler, Michael A.Markus, KleihOtt, GermanCarabaza, Neus GimenezDolors, Colomervan der Kuip, HeikoAulitzky, Walter E.
- [32] The CDK 4/CDK 6 Inhibitor PD0332991 significantly reduces cell growth via a G1 phase arrest in Mantle Cell Lymphoma cell lines and additively increases effects of IbrutinibONKOLOGIE, 2013, 36 : 198 - 198Zoellner, A-KDietzfelbinger, R.Hutter, G.Zimmermann, Y.Hiddemann, W.Dreyling, M.
- [33] The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC-Driven Mantle Cell LymphomaBLOOD, 2023, 142Pal, DhananjayaArditti, Page MangumMaddeboina, KrishnaiahMcHale, Cody C.Yang, Hsih-TeYada, BharathDryden, Hailey LynnFoureau, David M.Durden, Donald L.
- [34] Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) CellsBLOOD, 2017, 130Sun, BaohuaFiskus, WarrenRaina, KanakQian, YiminCrew, AndrewSaenz, Dyana T.Mill, Christopher PeterNowak, Agnieszka J.Saenz, David N.Crews, Craig M.Bhalla, Kapil N.
- [35] Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT InhibitionBLOOD, 2012, 120 (21)Chiron, DavidMartin, PeterDi Liberto, MaurizioHuang, XiangaoEly, Scott A.Lannutti, Brian J.Leonard, John P.Mason, Christopher E.Chen-Kiang, Selina
- [36] SENEX-mediated CDK4/6 inhibition promotes senescence and confers apoptosis resistance in B-cell non-Hodgkin lymphomaBIOCELL, 2024, 48 (03) : 453 - 462Wang, JiyuYi, LiuyingHuang, KekeWang, YangyangWang, HuipingZhai, Zhimin
- [37] Combination efficacy of HDAC inhibitor vorinostat and CDK-4/6 dual inhibitor palbociclib against therapy-resistant mantle cell lymphomaCANCER RESEARCH, 2017, 77Chaturvedi, Nagendra K.Hatch, Nathan D.Sutton, Garrett L.Kling, Matthew J.Vose, Julie M.Joshi, Shantaram S.
- [38] Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell LymphomaBLOOD, 2011, 118 (21) : 1596 - 1596Mason, Christopher E.Di Liberto, MaurizioHuang, XiangaoChiron, DavidBretz, JamiesonAbdallah, RamseyEly, Scott A.Knowles, Daniel M.Martin, PeterLeonard, John P.Chen-Kiang, Selina
- [39] CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphomaCANCER LETTERS, 2024, 597Wang, YaliChen, JianfengGao, YanChai, Kelila Xin YeHong, Jing HanWang, PeiliChen, JinghongYu, ZhaoliangLiu, LizhenHuang, ChengTaib, Nur Ayuni MuhammadLim, Kerry May HuifenGuan, PeiyongChan, Jason YongshengHuang, DachuanTeh, Bin TeanLi, WenyuLim, Soon ThyeYu, QiangOng, Choon KiatHuang, HuiqiangTan, Jing
- [40] CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIBHAEMATOLOGICA, 2017, 102 : 575 - 575Fischer, L.Mayer, A.Irger, M.Freysoldt, B.Zimmermann, Y.Hutter, G.Hiddemann, W.Dreyling, M.